

Refine Search

Search Results -

Terms	Documents
L2 and antibod\$3	116

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L3

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, October 11, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<u>L3</u>	L2 and antibod\$3	116	<u>L3</u>
<u>L2</u>	L1 and diagnos\$3	118	<u>L2</u>
<u>L1</u>	ubiquitin adj fusion adj protein	250	<u>L1</u>

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 15:16:42 ON 11 OCT 2005)

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, SCISEARCH, USPATFULL,
PCTFULL'

ENTERED AT 15:17:19 ON 11 OCT 2005

L1 2272210 S UBIQUITIN(W)FUSION(W)PROTEIN? OR POLYPEPTIDE? OR
PEPTIDE?

L2 6 S DIAGNOS? S ANTIBOD?

L3 439650 S ANTIBOD? AND L1

L4 129318 S L3 AND DIAGNOS?

L5 229019 S L1(S)ANTIBOD?

L6 6 S L1 AND L2



L7 516 S UBIQUITIN(W)FUSION(W)PROTEIN

L8 151145 S ANTIBOD?(S)DIAGNOS?

L9 129 S L7 AND L8

L10 129 DUP REM L9 (0 DUPLICATES REMOVED)

L11 28 S L9 AND 1960-1998/PY



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show 20 Sort by Send to

All: 1 Review: 0 X

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI \(Cubby\)](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

1: Mol Immunol. 1997 Nov-Dec;34(16-17):1113-20.

[Related Articles, Links](#)**Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope.****Dalum I, Jensen MR, Gregorius K, Thomasen CM, Elsner HI, Mouritsen S.****M&E Biotech A/S, Horsholm, Denmark.**

Self proteins are handled in the same way as foreign proteins by antigen presenting cells, but because of T-cell tolerance the presentation of self peptides does not normally lead to T cell activation. By providing physically linked T-cell help it is possible to overcome the B cell non-responsiveness toward self antigens. We have shown previously that a very potent antibody response, cross-reactive with a self protein, can be rapidly induced by immunizing with a recombinant immunogen consisting of the self protein with a foreign immunodominant T helper epitope inserted into its sequence (Dalum, I., Jensen, M. R., Hindersson, P., Elsner, H. I. and Mouritsen, S. (1996) J. Immunol. 157, 4796). In this study we compare this approach for inducing autoantibodies against a self protein with the traditional method of conjugating the self antigen to a foreign carrier protein. The highly conserved self protein ubiquitin with an inserted epitope from ovalbumin (UbiOVA) is used as a model protein and compared to two traditionally conjugated immunogens consisting of ubiquitin chemically conjugated to a peptidic T helper epitope or to ovalbumin. The traditionally conjugated immunogens induce much slower and low titered ubiquitin specific antibody responses than the recombinant construct which also is capable of inducing antibodies directed against a much broader range of potential ubiquitin B cell determinants than the chemically conjugated immunogens. All three constructs are processed by antigen presenting cells and ovalbumin derived T cell epitopes are presented to T helper cells. From these observations it seems likely that the presence of non-shielded autologous B cell determinants on the immunogen is critical for the ability to induce a strong autoantibody response with a diverse fine specificity. Furthermore, the ubiquitin specific antibodies induced by UbiOVA contain higher levels of IgG2a/b relative to IgG1 compared to the conjugates. We therefore

speculate that the insertion of a T cell epitope directly into the self antigen could possibly induce an immune response with a different Th1/Th2 balance than a response induced with traditional conjugates.

PMID: 9566759 [PubMed - indexed for MEDLINE]

Display Show Sort by Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 6 2005 04:38:59